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The challenges to healthcare systems are common worldwide. The need to identify new 
treatments and solutions that reduce the burden on society is top priority for all public policy 
makers. This study investigates the role of patients and caregivers as innovators. Drawing on 
Rogers’ diffusion of innovations theory, we aim to understand how well lead users in the 
medical field are communicating their inventions. Based on a sample of 248 submissions in a 
patient innovation platform, this study assesses the likelihood of innovation diffusion. 
Overall, our results show that patient innovations are not communicated effectively online. 
Nevertheless, the levels of radicalness and complexity positively impact on the quality of 
communication. Our findings are important as communication strongly influences diffusion 
and, consequently, adoption. Hence, educating users on how to better communicate their 
solutions on dedicated online communities is appointed as the key to boosting adoption by 
others, which in turn leads to increased social welfare. Further implications for theory and 
practice are discussed.  
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Os desafios aos sistemas de saúde são comuns em todo o mundo. A necessidade de identificar 
novos tratamentos e soluções que reduzam o fardo na sociedade é uma prioridade para todos 
os países. Este estudo investiga o papel de pacientes e prestadores de cuidados de saúde 
enquanto inovadores. Com base na teoria da difusão de inovações de Rogers, temos como 
objectivo perceber quão bem os lead users do campo médico estão a comunicar as suas 
invenções.  Baseado numa amostra de 248 submissões numa plataforma de soluções 
desenvolvidas por pacientes, este estudo avalia a probabilidade de difusão das inovações. Em 
suma, os resultados da nossa análise demonstram que as inovações desenvolvidas por 
pacientes não são eficazmente comunicadas online. No entanto, os níveis de radicalidade e 
complexidade têm um impacto positivo na qualidade da comunicação. Os nossos resultados 
são importantes pois a comunicação influencia fortemente a difusão e, consequentemente, a 
adopção. Portanto, a educação de utilizadores na forma de comunicar as suas soluções em 
comunidades online dedicadas é apontada como a chave para aumentar a adopção por outros, 
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In recent decades, life expectancy has been growing exponentially (World Health 
Organization, 2015). This is a major achievement, yet as the population ages, health spending 
rises alongside. The need to meet an increasing demand for health care services has lead to an 
overall struggle to reduce costs. In fact, medical expenses are expected to accelerate by an 
average of over 5% every year until 2018 (Deloitte, 2015). This increase is not only due to an 
aging and growing population, but also because of a rising prevalence of chronic diseases, the 
growth of emerging markets, and advances in treatments and technologies. 
As the world recovers from an economic crisis, the pressure to reduce costs builds and the 
search for newer, more efficient business models and operating processes intensifies. 
Innovation has been identified as a solution to alleviate this economic burden in public health 
(Kuusisto et al., 2013). The concept of user innovation, which revolves around the idea that 
one is more likely to find a solution to a problem as it becomes more pressing and harder to 
deal with, has been extensively studied by many researchers. Namely, von Hippel (1986, 
1994, 1998, 2005) has dedicated a significant amount of his work to the user innovation 
theory, which agrees with the English proverb ‘necessity is the mother of invention’ 
(anonymous) by arguing that people will engage in innovative behaviours when unsatisfied 
by existing solutions. 
However, despite the research attention the concept of user innovation has been receiving 
(Schreier and Prügl, 2008; Shah and Tripsas, 2007; von Hippel, 2015), its study in the specific 
context of health care is far from being exhausted. The topic gains relevance as nowadays 
access to information and, consequently, knowledge, a vital component of innovation, is 
becoming easier and no longer limited to a few. Advances in technology have created the 
ideal conditions for user innovation and the potential of patients and caregivers as developers 
of solutions has yet to be studied.  
The innovative capabilities of users in the healthcare sector have already been proven (Lettl et 
al., 2006; Shah and Robinson, 2006; Oliveira et al., 2014), though little has been done so as to 
instigate this behaviour. To best of our knowledge, only one platform has the goal of 
promoting and facilitating the sharing of solutions developed by patients and their non-
professional caregivers1. Communication plays a huge role in the diffusion of new ideas 
(Rogers and Shoemaker, 1971) and we truly believe the study of the former can lead to 
enhancements of the latter, thus it is important, firstly, to have a platform to share the ideas 
and, secondly, to communicate them well. Given the early stage of the Patient Innovation 




project, much can still be studied and subsequent conclusions used for development and 
improvement of not only the platform itself, but also of the entire health care system, which is 
in candid need of a reform. 
Research on user innovativeness introduced us to the concept of lead users (von Hippel, 
1986), a distinct group of users who experience a need well ahead of the rest of the market. 
Evidence shows that lead users are likely to significantly benefit from developing their own 
solutions and that these self-developed innovations are expected to be radical. We believe that 
the level of radicalness influences the ability to communicate an innovation, as new-to-the-
world solutions fall outside consumers’ mental schema and their benefits are sometimes not 
understood by potential users (Mugge et al., 2013).  
Rogers (1995) developed the diffusion of innovations theory, which attempts to explain the 
process of communication entailed in the spreading of messages that are perceived as 
somewhat new ideas. The theory has been broadly studied in several fields, such as 
Education, Geography, and even Public Health and Medical Sociology. However, the 
application of the innovation diffusion theory to the user innovation concept has still not been 
studied, which is what we hereby propose to do. 
User-developed solutions are non-commercial in nature; their initial goal is self-benefit, even 
if they end up being commercialized in a later stage. Hence, the question we wish to address 
with this work relates to the diffusion process of user innovations and to what extent it 
resembles the one of traditional innovations, developed by producers. Ultimately, we have 
two goals: to evaluate the role of user innovation platforms as spotlights to the community 
and catalysts of diffusion, and to help with the empowerment user innovators as marketeers of 
their own inventions.  
The importance of studying this matter has been growing exponentially, as the phenomenon 
of user-driven innovation grows worldwide. According to Kuusisto et al. (2013), 3.7% of 
consumers in Japan created at least one user innovation in the previous three years, this means 
about 4.7 million consumers, unsatisfied with the offers in the market, who decided to 
actively engage in innovation to solve a personal need. This number is 5.2% in the USA, 
5.4% in Finland, 6.1% in the United Kingdom and 6.2% in the Netherlands. 
Nonetheless, these consumer innovations are not being diffused. In Finland, only 18.8% of all 
user innovations are adopted by other users or firms (Kuusisto et al., 2013). In the UK the 
frequency is 17.1% (von Hippel et al., 2012), 6.1% in the USA, and this number drops to 
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5.0% in Japan (Ogawa and Pongtanalert, 2011).2  On the one hand, these results prove how 
meaningful to other users these innovations can be, and on the other, they show how about 
80% of all consumer innovations do not even become available to the wider society. This 
insufficient diffusion indicates a potential social welfare loss (Henkel and von Hippel, 2005), 
which is why it is imperative to create incentives to share. 
Kuusisto et al. (2013) show how consumer willingness to freely share their innovations is 
almost 85%, being the biggest motivation the potential to help others (54%). However, 
willingness to share and efforts to actually to it are not aligned, unfortunately. The fraction of 
innovators who have done any kind of effort to diffuse their own solutions averages a mere 
21.2%. This low value reflects a clear lack of incentive to share, because, unlike producer 
innovations, consumer innovations are developed for self-benefit and not for selling or 
licensing. 
User innovation is especially relevant in the health sector, as these patient-developed 
solutions may lead to breakthroughs in the medical field or even save lives. Typically, the 
starting point for these innovative users are the difficulties they face in their daily lives, for 
which a solution has yet to be found (Lettl et al., 2006). This lack of existing medical 
equipment, technology or therapy to meet their needs instigates patients to search for more 
suitable solutions, giving them a ‘motivation induced by problem’, as defined by Lettl et al. 
(2006). Studies on creativity also show that high problem pressure propel a creative behaviour 
(Boden, 1994; Collins and Amabile, 1999; Csikszentmihalyi, 1988). 
A study conducted in Finland shows that 5.4% of patients and their family members have 
experienced at least one particular problem regarding the functioning of the medical sector in 
the past three years and have consequently identified at least one solution to solve it. This rate 
is 5.7% for doctors, and 15.3% for nurses (Kuusisto et al., 2013). These numbers suggest that 
user innovation can indeed start a revolution in the management of public sector activities. In 
particular, we believe it is the key to renewing the healthcare sector, which is struggling to 




	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 Percentages indicate what fraction of innovations has been diffused to peers or commercial 
producers. New venture creation as a diffusion mechanism is not included. 
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2. Literature Review 
This chapter is dedicated to the review of the literature gathered and analysed in the 
development of the present thesis. It is the literary foundation of this paper and, thus, 
comprises the most important theoretical bases and concepts inherent to its elaboration and 
posterior understanding.  
2.1. Sources of Innovation 
2.1.1. Innovation: concept, importance and prevalence. 
An innovation, as defined by Zaltman, Duncan and Holbek (1973, p.10), is ‘any idea, 
practice, or material artefact perceived to be new by the relevant unit of adoption’ and it may 
vary in the degree of newness to an adopting unit. This distribution is partly detained by the 
notion of radicalness. Radical innovations are fundamental changes that represent 
revolutionary deviations in technology, they signify clear departures from existing practice 
and lead to shifts in consumer usage patterns (Duchesneau, Cohn and Dutton 1979; Ettlie 
1983; Mugge and Dahl, 2013). Incremental innovations are minor improvements or simple 
adjustments in current products or technology, which lead to improved performance (Mugge 
and Dahl, 2013; Munson and Pelz, 1979).  
Globalization has contributed to an increased market competition, highlighting the importance 
of having a long-term competitive advantage. According to the authors, the answer lies in 
constantly being innovative, meaning firms have to constantly differentiate its products and 
services (Popadiuk and Choo, 2006). 
Producers and designers within firms have been the only source of innovation for many years, 
however, the involvement and empowerment of consumers throughout the innovation process 
have become an increasing trend (von Hippel, 2005). Several studies have attempted to 
measure consumer perceptions with regards to user-designed products, such as the one 
conducted by Schreier and colleagues (2012), which shows a positive correlation between 
common design by users and the perceived innovation ability of a firm. 
The level of involvement of consumers in the innovation process may also range from 
minimal, such as customization or even co-creation, to substantial, where the end-user 
idealizes and further develops a solution to satisfy their own needs, having in mind personal 
gratification as opposed to commercialization (von Hippel, 2005). 
In addition, innovations differ in degree of openness. Open innovation is generally found to 
have a positive contribution towards innovation performance (Chesbrough, 2003; Dahlander 
and Gann, 2010; Enkel et al., 2010; Fu, 2012) and, given the informal nature of user 
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innovations, the potential gains from collaboration are greater than the possible drawbacks of 
disclosing an idea (Chesbrough, 2003). Keupp and Gassmann (2009) found that firms adopt 
open innovation to gain otherwise difficult access to external talents and resources, diversify 
risks and share uncertainties whilst promoting learning. Grandstrand et al. (1992) believe that 
technological convergence and the shortening of product cycle times are also two key 
advantages of using external sources of knowledge. 
2.1.2. User Innovation 
Users, as defined by von Hippel (2005, p.3), ‘are firms or individual consumers that expect to 
benefit from using a product or a service’. With a contrasting underlying motive, 
manufacturers seek to sell products or services, benefiting from the generated profits. 
Bearing this difference in intent to commercialize in mind, firms using the manufacture-
centric innovation process look for a differentiating factor that will maximize their sales. 
Thus, in order to maintain a competitive advantage, these organizations see the need to 
develop products and services in a closed way, resorting to the use of patents and copyrights 
in order to protect their investments. On the other hand, the user-centric model is 
characterized by its openness, as users’ major incentives to share are helping others and the 
hope that others might further improve their solutions (Kuusisto et al., 2013; von Hippel, 
2005).  
Von Hippel (1986) has contributed extensively to the literature on user innovations, having 
categorized user innovators as lead users by examining their unique set of characteristics. 
According to the author’s definition (1986, p.791), ‘lead users are users whose present strong 
needs will become general in a marketplace months or years in the future’. In addition to 
experiencing needs before others, lead users are bound to greatly benefit from obtaining a 
solution to their needs, leading them to innovate. 
Many researchers have since built upon the concept, suggesting that lead users’ innovative 
behaviour can also be seen in their faster and heavier adoption of new commercial products, 
when compared to ordinary users (Morrison et al., 2000; Schreier and Prügl, 2008; Urban and 
von Hippel, 1988). Moreover, Schreier, Oberhauser and Prügl (2007) uncover that lead users 
are more likely to exhibit stronger opinion leadership rather than opinion seeking tendencies. 
For example, a field where lead userness is seen to cause great impact is extreme sports such 
as sailplaning and kite surfing, because the ones heavily practicing these activities, the 
experts, are the first to face a given problem and the ones who will benefit the most from 
solving it (Schreier et al., 2007; Schreier and Prügl, 2008). 
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The belief that lead users possess the ability to innovate and satisfy their own needs is 
strongly related to the unique type of knowledge they acquire through experience (Caraça et 
al., 2009; Johannessen et al., 1999; Schreier et al., 2007; Schreier and Prügl, 2008). Tacit 
knowledge is linked to experience (Nonaka, 1994), it is inherent to users and a challenge for 
organizations to obtain (Popadiuk and Choo, 2006). Jensen et al. (2007, p.680) have defined 
two modes of innovation: the Science, Technology and Innovation (STI) mode, based on ‘the 
production and use of codified scientific and technical knowledge’ and the Doing, Using and 
Interacting (DUI) mode, which relies on ‘informal processes of learning and experience-based 
know-how’. Their study reveals that a combination of both modes should be used in order to 
achieve higher levels of innovativeness, hence emphasizing the significance of users in the 
innovation process.  
2.1.3. Diffusion of user innovations 
An important aspect of an innovation is not only its utility, but also its potential of adoption, 
which happens as a consequence of diffusion. As defined by Rogers (1995, p.5), ‘diffusion is 
the process by which an innovation is communicated through certain channels over time 
among the members of a social system’. An innovation’s adoption rate is determined by the 
users’ perceptions of its characteristics. These attributes consist of five variables: 
1) Relative Advantage: ‘the degree to which an innovation is perceived as better than the 
idea it supersedes’; 
2) Compatibility: ‘the degree to which an innovation is perceived as being consistent 
with existing values, past experiences, and needs of potential adopters’; 
3) Complexity: ‘the degree to which an innovation is perceived as difficult to understand 
and use’; 
4) Trialability: ‘the degree to which an innovation may be experimented with on a 
limited basis’; 
5) Observability: ‘the degree to which the results of an innovation are visible to others’. 
All of these variables have been proved to have a positive influence on adoption, to the 
exception of complexity which impacts adoption negatively. Hence, a successful 
communication of an innovation’s characteristics is of utmost importance, as they are the 
basis of the decision to adopt. 
Effective communication is defined as ‘a two way information sharing process which 
involves one party sending a message that is easily understood by the receiving party’ 
(TheBusinessDictionary.com). Communication theory (Shannon and Weaver, 1949) argues 
that a message must be clear in order to be de-codified and subsequently understood by its 
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receiver. In the context of sharing new ideas, the same principle is maintained; for an 
innovation to be adopted by its target, the latter must first understand it. Hence, for the above-
mentioned characteristics to play a role in the diffusion process, they must be communicated 
in a way that will be understood by others. 
In the particular setting of user innovations, it is common for lead users to engage in informal 
collaborations with other users when developing solutions, in order to increase speed and 
effectiveness through knowledge sharing (von Hippel, 2005). Organized communities can 
also significantly accelerate the processes of diffusion and testing, in numerous areas from 
software to physical products (Franke and Shah, 2003; von Hippel, 2005).  
By definition, user innovation is driven by the expected benefit of using the solution 
developed (von Hippel, 2005). The primary goal of these innovators is personal use, being the 
use by others sometimes not even considered. Thus, unlike producers, who have maximum 
profitability as a strategy, in the process of user innovation, diffusion is considered but an 
externality, meaning it will only be implemented for as long as its costs do not exceed the 
expected benefits (Fidélis, 2013; Raasch and von Hippel, 2012). 
Raasch and von Hippel (2012) determine two innovation diffusion channels: peer-to-peer and 
market forces. The former consists of free revealing and is associated to user innovations, 
whereas the latter usually has a financial cost and is the more traditional diffusion strategy of 
producers. Figure 1 illustrates this point. 
 
Figure 1 – The user and producer innovation and diffusion paradigms (Raasch and von Hippel, 2012) 
2.1.4. User entrepreneurship 
Researchers have not yet reached a consensus regarding the definition of innovation. 
Nevertheless, according to Popadiuk and Choo (2006), three concepts remain constant in the 
literature as inherent to the term: novelty, commercialization and/or implementation. The 
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dissociation from monetization seldom occurs in an advanced stage of a user innovation, 
regardless of initial intentions of self-benefit (von Hippel, 2005). 
The truth is that user innovations, as a means of solving pressing and urgent needs, might be 
transferable to other users with similar needs, and possibly even life-changing, especially in 
the medical context. Rare diseases are an example of a market that is under-catered to; orphan 
drugs are not attractive in commercial terms, for they require huge investments and offer 
limited returns, hence enhancing the conditions for user innovations to occur (Oliveira et al., 
2014). 
Market segmentation is a common technique used by producers to match the perceived needs 
of consumers. Yet, this process proves to be ineffective when the needs of users are highly 
heterogeneous; when highly specific needs arise, so does the propensity to innovate. In their 
study of software systems, Franke and von Hippel (2003) depicted that there is a positive 
correlation between the level of heterogeneity of users’ needs and their willingness to pay for 
personalized solutions.  
Shane and Venkataraman (2000) define entrepreneurship as the discovery, evaluation and 
exploitation of opportunities to create future goods and services. In broad terms, the main 
difference between user-entrepreneurs and a more traditional kind of entrepreneur is that the 
former intends to benefit from its products both by using and selling them. In some cases of 
user entrepreneurship, the formal and well-defined steps of product development might be 
blurred or skipped, as the entire process naturally evolves, giving birth to the term ‘accidental 
entrepreneur’ (Shah and Tripsas, 2007). 
Figure 2- entrepreneurial role of users (Lettl. et al., 2006) 
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As illustrated by Lettl. et al. (2006) in figure 2, the process of user innovation arises from a 
motivation to solve a pressing issue, which in turn leads to the user engaging in a role of 
inventor, articulating needs and idealizing prototypes. Another layer in the entrepreneurial 
role of users is the high degree of innovativeness, which the authors have found to be 
negatively correlated to manufacture involvement in early stages due to increased uncertainty 
of the market and the lack of technological development. Also, as radical innovations in the 
medical field, their application is usually just emerging and their market potential highly 
speculative. Moreover, a key factor leading to user entrepreneurship is the lack of 
competencies and resources the users have to transform their prototypes into actual 
marketable products, hence having to rely on external support. 
2.2. User Innovation in the Healthcare sector 
2.2.1. Patient Innovation 
Patient innovation (PI) is the notion of user innovation applied to the specific context of 
healthcare. According to Habicht et al. (2012), patient innovators are those who develop novel 
treatments, strategies, and medical or non-medical equipment to help them cope with a 
disease. For the purpose of this thesis, we will use a slightly broader definition of patient 
innovators, defining them as individuals, patients or caregivers, who develop a new offering 
with the intention of benefiting from its use, not commercialization (Shcherbatiuk, 2012; 
Czernin, 2013). 
2.2.2. Ideation and development of PI 
The development of highly specific medical solutions requires thorough understanding of user 
needs, which is obtained almost exclusively by experience and experimentation. Von Hippel 
(1994, 1998) defined this type of knowledge as ‘sticky’, for it is challenging and costly to 
transfer to third parties. In their study of users’ contributions to radical innovation, Lettl et al. 
(2006) used innovative medical doctors as a sample. These possessed both the in-depth 
scientific knowledge within the domain of surgery and the knowledge from previous 
experience of using existing medical equipment. Therefore, they had enough knowledge to 
conceptualize a solution, but lacked the technical knowledge to manufacture it, which is why 
the collaboration of users and producers in early stages of the development process proved to 
be so successful.  
In addition to problem-induced motivation and prior knowledge, Lettl et al. (2006) outlined 
‘openness to new technologies’ as another fundamental condition for innovativeness. 
According to the authors, the fact that the users at study searched for solutions outside of the 
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medical domain was crucial in achieving radical innovations. Also, whether they had access 
to many or few resources for research, such as time, funds or help, was irrelevant as users 
who lacked access to these supportive elements displayed strong ‘intrinsic motivation’, 
another key enhancer of creative activities (Csikszentmihalyi, 1988). 
2.2.3. Diffusion of PI 
Patient-developed innovations, as solutions to highly specific needs, may appear to have 
minimal marketable potential. The intent to commercialize goes beyond the initial intrinsic 
motivation to solve a personal problem, however it is not uncommon for user innovations in 
the healthcare sector to naturally wind down the road of commercialization (Lettl et al., 
2006). The reasoning behind this phenomenon is two-folded; diffusion may happen less 
formally via peer-to-peer or more consciously via the forces of the marketplace (Raasch and 
von Hippel, 2012). 
In the first scenario, the user innovator shares their solution with individuals or a community 
of peers who display the same needs. Incentives to share are mostly philanthropic rather than 
commercial; given the particularity of the context, patient innovators see a genuine benefit 
from freely revealing and sharing their solutions (Franke and Shah, 2002; von Hippel, 2005). 
Diffusion is seen as an externality to the innovation process and the new solution may, or may 
not, attract the scientific community in order to be further studied and developed (Fidélis, 
2013). 
Users who follow the second channel assume, to different degrees, a more entrepreneurial 
role as innovators. According to Lettl et al. (2006), users who are willing and able to idealize 
a concept but lack the skills or resources to create a prototype usually invest the time and 
efforts to look for external help with some degree of expertise. Hence, diffusion occurs as part 
of the problem-solving process, due to lack of competencies and/or resources. 
2.3. Patient Innovation Adoption 
2.3.1. Active users in healthcare 
Active patients, as the term suggests, are those who actively seek for solutions to their 
medical problems and, in contrast with passive patients, are engaged in the management of 
their health and take control of the decision-making process (McAllister et al., 2012; Oliveira, 
2014). For example, an active patient would take into consideration several doctors’ opinions, 
search for other solutions outside the medical community and measure all their options before 
committing to a treatment. A passive patient accepts whichever treatment their doctor 
suggests without questioning it or looking for alternatives. 
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All patient innovators are active users, yet the inverse is not necessarily true. The majority of 
active patients will look for existing solutions, but only a few will actually engage in the 
innovation process. The former are the most likely adopters of the solutions developed by the 
latter (von Hippel, 2005).  
2.3.2. The sharing process 
The adoption process of user innovations in the healthcare context is quite particular, in the 
sense that it is not vital for the success of a user innovation, bearing in mind the goal of these 
solutions is to benefit from personal use. Thus, unlike the solutions developed by producers 
and organizations, the adoption by others is somewhat irrelevant (Raasch and von Hippel, 
2012). 
Furthermore, because the topic is people’s health, it is of high overall relevance because user 
innovations in this field might yield positive externalities of great magnitude. It is of social 
interest to have organized communities dedicated to this purpose so as to boost sharing and 
collaboration among users. In fact, the sharing itself has been linked to advances in the 
innovation process, such as improvements of the solution developed after receiving feedback 
from other patients. In a more advanced stage of the development process, innovators are 
usually more concerned with the opinions of other patients, who are potential adopters, than 
with sharing their solutions with doctors or complying with validation requirements or 
regulations (Fidélis, 2013). 
Measuring the success of a patient innovation is a challenging endeavour, as the usual 
measure of adoption is sales and this is in some cases non-existent. Going back to the 
definition of a user innovation, a solution is successful if it fulfils its main goal of self-benefit. 
Hence, any posterior diffusion and/or adoption by others is purely profit. 
To the best of our knowledge, there is no model conceptualized for predicting the adoption of 
non-technological innovations, which is why we resorted to innovation characteristics 
research, which ‘describes the relationship between the attributes or characteristics of an 
innovation and the adoption and implementation of that innovation’ (Tornatzky and Klein, 
1982). According to the authors, the ideal study should be predictive, rather than 
retrospective, which is in line with the present work, where most of the innovations (66%) 
have still not been implemented or commercialized.  
Given this literature gap - the lack of a model to predict patient innovation adoption - we 
hereby propose to study the potential adoption of patient-developed solutions by measuring 
the factors we already know play a role in this process. 
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Diffusion and communication are tied together (Rogers, 1995) and in order to boost the 
former, the latter must be effective. A successful message reception is one of two key 
elements of communication effectiveness, and in order to augment the likelihood of this 
scenario happening, the same message must be clearly voiced, which is the second key 
element. Patient-developed solutions have the potential to create highly positive externalities, 
yet for this to occur they must be effectively communicated. However, diffusion of user 
innovations is considered a secondary activity to the process and not enough efforts are 
directed into the sharing of an innovation, which leads us to our first grounding hypothesis: 
 H1 = The average quality of communication of patient innovations shared online is 
low. 
Furthermore, research established that user innovators are more likely to create radical 
innovations because of their lead-userness; since they feel a need way before others and 
intend to use their innovation for own benefit, they are likely to create something that falls 
outside the boundaries of convention and satisfies very specific needs (von Hippel, 1986). 
Moreover, the definition of a radical innovation shows that highly innovative solutions 
generally do not fit into the mental schema of consumers (Dewar and Dutton, 1986; Mugge et 
al., 2013). They sometimes lead to entirely new product segments or categories and users do 
not understand what the product is for as they have yet to experience a need for it. Hence, the 
communication of radical innovations needs to be quite detailed in order for the message to be 
clearly received by potential adopters (Creusen and Schoormans, 2005). Thus leading to our 
second hypothesis: 
 H2 = Radical patient innovations have a higher quality of communication than 
incremental ones. 
Moreover, Jensen et al. (2007) argues that experience-based knowledge (DUI), when 
combined with more technical knowledge (STI), is key to achieving higher degrees of 
innovativeness. Different types and degrees of knowledge also contribute to higher or lower 
levels of complexity of an innovation.  
Zaltman et al. (1973) state that the complexity of an innovation undoubtedly impacts its 
acceptance. The authors believe that, in general terms, the more complex an innovation is in 
terms of operating, the slower its acceptance will be. They do not define the concept, but 
explain that complexity can be displayed on two levels: on the one hand, the innovation may 
contain complex ideas, and on the other, the actual implementation of the innovation may be 
complex. For purpose of this thesis, the first manifestation was considered. Given their 
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inherent complexity and substantial amounts of technical knowledge, these solutions are 
harder to communicate, so: 
H3 = The quality of communication of less complex innovations is higher than the 
quality of communication of more complex innovations. 
All in all, an innovation might be great, in the sense that it solves pressing issues common to a 
large community. However, if no one besides from its developer knows about it, the solution 
is not living up to its full potential. In order to help several people and increase social welfare, 
the user innovation must be shared. Having an online platform created for this purpose, it is 
then the innovator’s responsibility to communicate its solution in a way that is clear to 
everyone and will be understood by others with the same needs. Only through effective 
communication will a patient innovation be able to create positive externalities that will 
maximize its value. But user innovators are usually not marketing experts, which is why we 






3.1. Secondary Data  
To generate valid and reliable results, we used data from a social network designed to share 
and promote solutions developed by patients and non-professional caregivers – www.patient-
innovation.com – the first and only one of its kind, to our knowledge. Anyone can access the 
platform and browse through the innovative solutions already shared. People are encouraged 
to become registered users, as this free feature allows one to join patient groups related to 
their specific condition, where the sharing of knowledge among users is stimulated. Also, 
registering in the platform enables the publishing of new self-developed solutions. 
Given that users actively search for this platform and make the conscious decision of freely 
revealing their ideas for the community’s sake, we believe they capture the lead-userness we 
intend to study, and are therefore an appropriate sample. The database used in this work 
consists of 248 posts from users describing the issues they faced and the solutions they 
developed. These people are from over 16 countries and bring awareness to more than 85 





We started by separating actual innovations from mere testimonials or ideas, so that the 
former could be object of study and the latter disregarded. This filtration process was made 
using the previously mentioned definition of innovation by Zaltman, Duncan and Holbek 
(1973, p.10): ‘any idea, practice, or material artefact perceived to be new by the relevant unit 
of adoption’.   
The categorization of posts as innovations or non-innovations was performed by an expert in 
the topic and consisted in verifying whether, or not, the solution described in the platform 
fitted this definition. If it did, then it could be used for the purpose of this study, if not, it 
would not be considered. In the end, 164 solutions (66%) were considered to fulfil the 
requirements of the above definition and were thus contemplated as innovations. The 
remaining 84 posts (34%) did not to fit the definition, hence were labelled as non-innovations. 
This first step was crucial in maintaining the validity of the data, so that only actual 
innovations were object of study. Thereafter, other categorizations had to be made in order to 
look for any patterns among user innovations in the healthcare sector.  
3.2. Measurement of the Variables 
3.2.1. Complexity 
We also categorized the solutions by levels of complexity, as within the group of innovations 
there were visible disparities in this regard and the literature considers this one to be an 
important variable for diffusion and adoption by others (Damanpour, 1988; Pelz, 1985). For 
this categorization, complexity was defined as the degree of difficulty of ideating and 
developing a solution, thus a qualitative approach was used to evaluate the level of 
complexity of the ideas involved in the innovation process. 
Due to the lack of an approved scale to measure this variable, experts’ perceptions were used 
to rate each innovation on a three-point scale (low, medium or high) in terms of apparent 
difficulty of idea generation and effort involved in the development process. The degree and 
type of knowledge used were also considered in this rating process, as Damanpour (1988, 
p.551) defined complexity as ‘the degree of special knowledge available to the organization’. 
In this case, the perceived amounts of both technical and experience-based knowledge used 
by the innovators were considered. The second manifestation of complexity, regarding ease-
of-use and implementation, was not taken into consideration. To avoid bias, three raters 
graded all innovations individually, having as reference the same definition of complexity and 




Radicalness is another variable already proven to affect diffusion and implementation 
(Damanpour, 1988). For the measurement of this variable, a scale built and tested by Dewar 
and Dutton (1986) was used. Innovations were rated on a three-point scale indicating whether 
each innovation: (1) had no new knowledge contained in the machine or process; (2) 
represented an improvement over existing technology; or (3) represented a major 
technological advance. The ratings of three judges were compared and the average value used 
to establish whether an innovation belonged to the radical (score ≥ 2.5) or the incremental 
(score < 2.5) categories. 
3.2.3. Communication 
To best of our knowledge, an agreed-upon rating system to evaluate the quality of sharing of a 
message does not exist. Thus, an index was created to measure the communication quality of 
the innovations shared in the Patient Innovation platform. 
This new variable was constructed as a combination of seven characteristics of an online-
shared innovation, having as a basis Rogers’ (1995) diffusion of innovations theory. One of 
the four main elements in the diffusion of new ideas is communication. It is the process by 
which participants create and share information with others so as to reach a mutual 
understanding. Bearing in mind that the majority of people evaluate an innovation through the 
subjective appraisals of others, rather than by relying on scientific research presented by 
experts, an online presence is a catalyst for diffusion.  
However, whilst having the Internet as a mass communication channel is positive in creating 
awareness of the innovations, it can be quite ineffective in forming and changing attitudes 
towards an idea. This difficulty in influencing the decision to adopt or reject an idea happens 
because the interpersonal, more humanistic components of communication are easily lost 
when sharing a message online. Hence, even though the platform does not allow users to 
physically share their innovations with others, providing some sort of visual aid, like pictures, 
sketches, or videos, can help potential adopters to better understand the concept, i.e. decode 
the message (Zhao et al., 2009).  
Moreover, Rogers (1995) points out five characteristics of an innovation which determine its 
rate of adoption: relative advantage, compatibility, complexity, trialability and observability. 
As the purpose of this variable is not to evaluate the innovation itself, but rather to measure 
the quality of its sharing, assessing the above mentioned attributes is irrelevant in the 
construction of this index. Yet, all these characteristics will indeed be studied and weighed in 
by users when deciding whether to adopt, or not, an innovation (Tornatzky and Klein, 1982). 
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Hence, in order to be considered by potential adopters, they must be clear to them, which is 
why the mentioning of these five characteristics in the description of an innovation is 
fundamental. 
Furthermore, communication is all about the sharing of knowledge, and even though 
sometimes too much information might be counter-productive as it becomes confusing to the 
receiver, for the purpose of this study, an assumption was made that more information is 
positive, as it translates into a more informed decision-making process and also because 
having a greater online presence boosts diffusion. 
To sum up, the index was built as a combination of seven binary variables, in the form of 
seven questions to yes or no answers. Basically, each solution was attributed a value between 
0 and 7, according to how many items were checked from the following list of questions. 
 
1) Visual: Is there a visual support (picture/video/sketch) of the innovation? 
   2) Compatibility: Are reasons to innovate shared?  
3) Complexity of Use: Is there an explanation on how to use the innovation (or is it 
obvious)? 
4) Relative Advantage: Is the innovation compared with alternatives?  
5) Observability: Are the beneficial outcomes of using the innovation explicit?  
 6) Trialability: Is it clear how to acquire/replicate innovation? 
   7) Hyperlink: Is there a link for additional information?  
 
Three raters were given the task of applying questions 2 through 6 to every innovation post. 
Given the objective nature of questions 1 and 7, only one rater was required to answer them. 
If the answer to one of these questions was positive, a 1 was attributed. A 0 was given 
otherwise. Subsequently, the variables were simply added up to obtain a final index value for 










4.1. Descriptive Statistical Analysis 
In order to test our proposed hypotheses, primary data was collected in the form of variable 
measurements by three judges. The ability to use this gathered data is dependent on its 
statistical reliability; variables can only be used if proven to have measured what they were 
designed to. Therefore, seven reliability tests were preformed to check for inter-rater 
agreement in the Complexity and Radicalness variables, and for five (Compatibility, 
Observability, Complexity of Use, Trialability, and Relative Advantage) of the 
Communication Index items3. 





Judge1 1.8720 .79226 164 
Judge2 1.6402 .68182 164 
Judge3 1.6463 .74095 164 
Table 1 – Item Statistics for judges’ measurements of Complexity variable 
 




95% Confidence Interval F Test with True Value 0 
Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .557a .472 .638 4.779 163 326 .000 
Average Measures .791 .728 .841 4.779 163 326 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition. The between-measure variance is excluded from the 
denominator variance. 
Table 2 – Inter-rater Reliability Results for Complexity variable 
 
Table 1 depicts the mean values of the measurements of complexity by judges 1, 2 and 3 for 
all 164 observations. The three means are quite similar in value, being Judge1’s slightly 
higher (M1=1.87) than the other judges’ (M2=M3=1.64). This tells us that the variable in 
question is likely to be measuring what it is supposed to. But our confirmation of validity is 
shown by a statistically significant (p < 0.05) interclass correlation of ICC=0.79 (ICC > 0.7), 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  




which tells us the Complexity variable has been accurately measured and can be used in our 
analysis. 
 
• Testing for inter-rater agreement in Radicalness 
Item Statistics 
 Mean Std. Deviation N 
Judge1 1.8293 .72306 164 
Judge2 1.5549 .76946 164 
Judge3 1.9024 .80808 164 
Table 3 – Item Statistics for judges’ measurements of Radicalness variable 
 
 




95% Confidence Interval F Test with True Value 0 
Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .495a .404 .582 3.942 163 326 .000 
Average Measures .746 .671 .807 3.942 163 326 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition. The between-measure variance is excluded from the 
denominator variance. 
Table 4 – Inter-rater Reliability Results for Radicalness variable 
 
Table 3 illustrates the individual means for the measurements of radicalness by all three 
judges, being Judge2’s somewhat lower (M2=1.55) than the rest (M1=1.82 and M3=1.90). Yet, 
average measures of interclass correlation of ICC=0.74 (ICC > 0.7) significant to a 5% level 
validate our variable and allows for its use in the testing of hypotheses. 
 
• Testing for inter-rater agreement in Compatibility 
 
Item Statistics 
 Mean Std. Deviation N 
Judge1 .8720 .33517 164 
Judge2 .9512 .21607 164 
Judge3 .8171 .38779 164 











95% Confidence Interval F Test with True Value 0 
Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .469a .377 .559 3.653 163 326 .000 
Average Measures .726 .645 .792 3.653 163 326 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition. The between-measure variance is excluded from the denominator 
variance. 
Table 6 – Inter-rater Reliability Results for Compatibility variable 
 
Measurement means of all three judges for the 164 observations are shown in table 5. Their 
similarity (M1=0.87, M2=0.95, M3=0.81) leads to the interclass correlation of ICC=0.73 seen 
in table 6. As this value shows statistical significance (p < 0.05) and is over 0.7, one can 
assume the measurements for the Compatibility variable are valid and may be used for 
analysis. 
 
• Testing for inter-rater agreement in Observability 
Item Statistics 
 Mean Std. Deviation N 
Judge1 .8110 .39273 164 
Judge2 .9329 .25091 164 
Judge3 .7378 .44118 164 
Table 7 – Item Statistics for judges’ measurements of Observability variable 
 




95% Confidence Interval F Test with True Value 0 
Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .446a .352 .537 3.411 163 326 .000 
Average Measures .707 .619 .777 3.411 163 326 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition. The between-measure variance is excluded from the 
denominator variance. 
Table 8 – Inter-rater Reliability Results for Observability variable 
 
As seen in table 7, means differ among judges (M1=0.81, M2=0.93 and M3=0.73), which tells 
us that measurements for Observability were not unanimous for some observations. However, 
a reliability test, presented in table 8, demonstrates an acceptable degree of correlation within 
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classes (ICC=0.71). It is just over 70% thus this variable is considered reliable and may be 
used for our hypotheses testing. 
 
• Testing for inter-rater agreement in Complexity of Use 
Item Statistics 
 Mean Std. Deviation N 
Judge1 .7195 .45061 164 
Judge2 .7927 .40663 164 
Judge3 .8537 .35453 164 
Table 9 – Item Statistics for judges’ measurements of Complexity of Use variable 
 




95% Confidence Interval F Test with True Value 0 
Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .456a .363 .547 3.519 163 326 .000 
Average Measures .716 .631 .784 3.519 163 326 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition. The between-measure variance is excluded from the 
denominator variance. 
Table 10 – Inter-rater Reliability Results for Complexity of Use variable 
 
Means for the measurements of judges 1, 2 and 3 for Complexity of Use are represented in 
table 9, where some disparities can be observed (M1=0.72, M2=0.79, M3=0.85). Nonetheless, 
average measures of interclass correlation shown in table 10 (ICC=0.72) prove the validity of 
the measurements to a level of significance of 5%.  
 
• Testing for inter-rater agreement in Trialability 
Item Statistics 
 Mean Std. Deviation N 
Judge1 .4207 .49519 164 
Judge2 .4451 .49850 164 
Judge3 .5305 .50060 164 












95% Confidence Interval F Test with True Value 0 
Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .535a .448 .618 4.457 163 326 .000 
Average Measures .776 .709 .829 4.457 163 326 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition. The between-measure variance is excluded from the 
denominator variance. 
Table 12 – Inter-rater Reliability Results for Trialability variable 
 
 
Item statistics for measurements of Trialability are depicted in table 11, where a similarity in 
means can be observed, being Judge3’s (M3=0.53) somewhat greater than the others 
(M1=0.42 and M2=0.45).  A reliability test shows that there is a meaningful (ICC > 0.7) and 
statistically significant (p < 0.05) interclass correlation of ICC=0.78. Hence, this variable has 
been successfully measured and can be included in our data analysis. 
 
• Testing for inter-rater agreement in Relative Advantage 
Item Statistics 
 Mean Std. Deviation N 
Judge1 .3415 .47565 164 
Judge2 .4390 .49779 164 
Judge3 .2744 .44757 164 
Table 13 – Item Statistics for judges’ measurements of Relative Advantage variable 
 




95% Confidence Interval F Test with True Value 0 
Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .585a .502 .662 5.227 163 326 .000 
Average Measures .809 .752 .854 5.227 163 326 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition. The between-measure variance is excluded from the 
denominator variance. 
Table 14 – Inter-rater Reliability Results for Relative Advantage variable 
 
The last variable to be tested for inter-rater agreement was Relative Advantage and, even 
though means vary quite substantially within judges (M1=0.34, M2=0.44, M3=0.28), an 
interclass correlation of ICC=0.81 shown in table 14 tells us that this is the variable with 
highest consensus among raters and can thus be considered valid and used in future analysis. 
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Furthermore, the constructed communication index had to be tested for internal consistency: 






Items N of Items 
.897 .897 3 
Table 15 – Cronbach’s Alpha Reliability Statistics for Communication Index 
 
Item Statistics 
 Mean Std. Deviation N 
Judge1 4.7744 1.33993 164 
Judge2 5.1707 1.31350 164 
Judge3 4.8232 1.36537 164 
Table 16 – Item Statistics for Communication Index 
 
Inter-Item Correlation Matrix 
 Judge1 Judge2 Judge3 
Judge1 1.000 .695 .786 
Judge2 .695 1.000 .749 
Judge3 .786 .749 1.000 

















Alpha if Item 
Deleted 
Judge1 9.9939 6.276 .793 .644 .856 
Judge2 9.5976 6.536 .764 .590 .880 
Judge3 9.9451 5.966 .834 .698 .820 
Table 18 – Item-Total Statistics for Communication Index 
 
As can be seen in table 15, our constructed communication index has Cronbach’s alpha 
coefficient of α=0.897, which proves its internal consistency, meaning this variable can be 
considered reliable. This interpretation is further justified by looking at table 16, where 
similar means among judges can be seen (M1=4.77, M2=5.17, M3=4.82). In addition, table 17 
illustrates strong positive inter-item correlations (IIC1,2=0.70, IIC2,3=0.75, IIC1,3=0.79) and 
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corrected high item-total correlations presented in table 18 (ITC1=0.79, ITC2=0.76, 
ITC3=0.83) point towards the same conclusion of reliability. Thus, the scale is valid and the 
data is reliable, therefore it is justifiable to interpret scores that have been aggregated together. 
 
  Low Medium High 
Complexity 74 70 20 
Radicalness 66 73 25 



















Total 137 144 129 58 136 76 127 
% 0.835 0.878 0.787 0.354 0.829 0.463 0.774 
Table 20 – Communication Frequencies by Item 
 
Tables 19 and 20 give us an overview of the Independent (Complexity and Radicalness) and 
Dependent (Communication Index) variables. We can see that most solutions fall under the 
Low and Medium categories both in degree of complexity and radicalness, whereas only 20 
and 25 solutions, respectively, were considered to belong to the highest level. 
Regarding the Communication Index, table 20 illustrates each one of the seven items that 
construct it and their individual total scores. Highest scores belong to the Visual (nvisual=137) 
and Compatibility (ncompatibility=144) elements and with only less than half of the observations 
answering positively to these questions, Observability and Trialability received the lowest 
scores, nobservability=58 (35.4%) and ntrialability=76 (46.3%), respectively. 
4.2. Hypotheses Testing 
H1 = The average quality of communication of patient innovations shared online is low.  
Statistics 
COMMUNICATION   











 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 1.33 2 1.2 1.2 1.2 
2.00 1 .6 .6 1.8 
2.33 1 .6 .6 2.4 
2.67 6 3.7 3.7 6.1 
3.00 5 3.0 3.0 9.1 
3.33 5 3.0 3.0 12.2 
3.67 7 4.3 4.3 16.5 
4.00 17 10.4 10.4 26.8 
4.33 18 11.0 11.0 37.8 
4.67 12 7.3 7.3 45.1 
5.00 16 9.8 9.8 54.9 
5.33 11 6.7 6.7 61.6 
5.67 22 13.4 13.4 75.0 
6.00 17 10.4 10.4 85.4 
6.33 8 4.9 4.9 90.2 
6.67 9 5.5 5.5 95.7 
7.00 7 4.3 4.3 100.0 
Total 164 100.0 100.0  
Table 22 – Communication Frequencies 
 
In order to test our first hypothesis, the mean, median and mode of our Communication Index 
were computed (table 21) and a frequencies table was plotted (table 22). A mean of M=4.92 
out of a maximum possible score of 7 (~70%) tells us that patient innovators are not 
communicating as well as they could be. Any value below the optimal 7 is considered to be 
ineffective, as potential adopters make decisions on the basis of their evaluations of an 
innovation’s characteristics. Hence, the non-communication of even one of these 
characteristics hampers the decision-making process and lowers likelihood of adoption. In 
table 22, we can see that only 25% of all 164 solutions are considered to have a 
communication index of 6 or higher and that a mere 4.3% are communicated effectively 
(scored 7 out of 7). This proves our hypothesis that patient innovations are not being 
effectively communicated and shared in designated online communities, which might be the 





H2 = Radical patient innovations have a higher quality of communication than 
incremental ones. 
 
• One-way ANOVA for Radicalness (IV) and Communication (DV) 
Descriptives 
COMMUNICATION   
 N Mean Std. Deviation Std. Error 
95% Confidence Interval for 
Mean 
Minimum Maximum Lower Bound Upper Bound 
Low 66 4.3788 1.30362 .16046 4.0583 4.6993 1.33 7.00 
Medium 73 5.1827 1.02753 .12026 4.9430 5.4225 2.67 7.00 
High 25 5.6012 .91868 .18374 5.2220 5.9804 4.00 6.67 
Total 164 4.9230 1.22024 .09529 4.7348 5.1111 1.33 7.00 
Table 23 – Radicalness (IV) and Communication (DV) Descriptives 
 
Test of Homogeneity of Variances 
COMMUNICATION   
Levene Statistic df1 df2 Sig. 
2.982 2 161 .053 
Table 24 – Levene’s Test for Radicalness (IV) and Communication (DV) 
 
ANOVA 
COMMUNICATION   
 Sum of Squares df Mean Square F Sig. 
Between Groups 35.971 2 17.985 14.007 .000 
Within Groups 206.735 161 1.284   
Total 242.706 163    













Post Hoc Tests: 
Multiple Comparisons 
Dependent Variable: COMMUNICATION   






Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Low Medium -.80395* .19247 .000 -1.2593 -.3486 
High -1.22241* .26612 .000 -1.8519 -.5929 
Medium Low .80395* .19247 .000 .3486 1.2593 
High -.41846 .26259 .251 -1.0396 .2027 
High Low 1.22241* .26612 .000 .5929 1.8519 
Medium .41846 .26259 .251 -.2027 1.0396 
*. The mean difference is significant at the 0.05 level. 




Tukey HSDa,b   
RADICALNESS N 
Subset for alpha = 0.05 
1 2 
Low 66 4.3788  
Medium 73  5.1827 
High 25  5.6012 
Sig.  1.000 .199 
Means for groups in homogeneous subsets are displayed. 
a. Uses Harmonic Mean Sample Size = 43.573. 
b. The group sizes are unequal. The harmonic mean of the group sizes is used. Type I error levels are not 
guaranteed. 
Table 27 – Summary of Tukey HSD for Radicalness (IV) and Communication (DV) 
 
To put our second hypothesis to the test, we conducted a one-way ANOVA to test the impact, 
if any, of an innovation’s radicalness on its quality of communication. Hence, we defined 
Radicalness as our independent variable (IV), made up of 3 levels (Low, Medium, and High) 
and used Communication as our dependent variable (DV). In order to be able to use ANOVA 
and obtain valid results, 6 assumptions have to be met. Namely, the DV must be continuous 
(0-7), the IV should consist of two or more independent groups (3), independence of variables 
should be verified, there should be no significant outliers and our DV should be 
approximately normally distributed for our IV. 
After checking for these criteria, we conducted a Levene’s test (table 24) to verify 
homogeneity of variances. With a p-value over 0.05 (p=0.053), the null hypothesis that 
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variances across the three levels are the same cannot be rejected, which means we can 
proceed with our ANOVA analysis. 
Just by looking at table 23, some differences can be seen among the means of the different 
groups (Mlow=4.38, Mmedium=5.18, Mhigh=5.60), yet only in table 25 can we confirm their 
statistical significance. With a significance of 0.00, we can reject the null hypothesis that 
there is no difference in means across the levels. Furthermore, by looking at the post hoc tests 
in tables 26 and 27, we can verify the statistical significance of mean differences between 
Low and Medium radicalness (p=0.00), as well as Low and High (p=0.00), but not among 
Medium and High levels (p=0.25). 
Overall, this ANOVA tells us that radical solutions (high radicalness) have a higher 
communication score than incremental ones (low radicalness), proving our hypothesis that 
radical innovations are better communicated than incremental innovations. 
 
H3 = The quality of communication of less complex innovations is higher than the 
quality of communication of more complex innovations. 
 
• One-way ANOVA test for Complexity and Communication Index 
Descriptives 
COMMUNICATION   
 N Mean 
Std. 
Deviation Std. Error 
95% Confidence Interval for 
Mean 
Minimum Maximum Lower Bound Upper Bound 
Low 74 4.4416 1.26921 .14754 4.1476 4.7357 1.33 7.00 
Medium 70 5.2240 1.04051 .12436 4.9759 5.4721 3.00 7.00 
High 20 5.6505 .92715 .20732 5.2166 6.0844 4.00 7.00 
Total 164 4.9230 1.22024 .09529 4.7348 5.1111 1.33 7.00 
Table 28 – Complexity (IV) and Communication (DV) Descriptives 
 
Test of Homogeneity of Variances 
COMMUNICATION   
Levene Statistic df1 df2 Sig. 
1.826 2 161 .164 








COMMUNICATION   
 Sum of Squares df Mean Square F Sig. 
Between Groups 34.075 2 17.037 13.148 .000 
Within Groups 208.631 161 1.296   
Total 242.706 163    
Table 30 – One-way ANOVA for Complexity (IV) and Communication (DV) 
 
Post Hoc Tests: 
Multiple Comparisons 
Dependent Variable: COMMUNICATION   






Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Low Medium -.78238* .18980 .000 -1.2314 -.3334 
High -1.20888* .28689 .000 -1.8875 -.5302 
Medium Low .78238* .18980 .000 .3334 1.2314 
High -.42650 .28863 .304 -1.1093 .2563 
High Low 1.20888* .28689 .000 .5302 1.8875 
Medium .42650 .28863 .304 -.2563 1.1093 
*. The mean difference is significant at the 0.05 level. 




Tukey HSDa,b   
COMPLEXITY N 
Subset for alpha = 0.05 
1 2 
1.00 74 4.4416  
2.00 70  5.2240 
3.00 20  5.6505 
Sig.  1.000 .230 
Means for groups in homogeneous subsets are displayed. 
a. Uses Harmonic Mean Sample Size = 38.561. 
b. The group sizes are unequal. The harmonic mean of the group sizes is 
used. Type I error levels are not guaranteed. 




Finally, to test our third hypothesis about the impact of innovation complexity on quality of 
communication, we followed a similar approach as the previous one. We believe the one-way 
ANOVA is the best way to put our hypothesis to the test, as our IV (complexity) is three-
folded (Low, Medium, High) and our DV (Communication) is a scale from 0 to 7. All 164 
observations are independent, there is an absence of significant outliers and the DV is 
normally distributed among the three categories of complexity. A Levene’s test in table 29 
also validates the homogeneity of variances, as the null hypothesis cannot be rejected with a 
p-value of 0.164 (p > 0.05). 
After checking all assumptions, the ANOVA (table 30) confirms a statistically significant 
difference between groups (p=0.00). A more detailed analysis present in tables 31 and 32 
illustrates that mean difference of Medium and High levels of complexity are not significant 
(p=0.30), whereas between Low and the other two levels it is (p=0.00). 
All in all, looking at the group means and knowing their significance, we can conclude that 
higher complexity levels lead to higher communication indices, which rejects our hypothesis 
that less complex innovations are better communicated than more complex ones. In fact, this 
analysis proves that quality of communication increases with innovation complexity 





The aim of this work is to explore the diffusion process of user innovations in the medical 
field. As diffusion and communication go hand in hand (Rogers, 1962), we felt it was 
appropriate to study communication as a tool to enhance diffusion and boost adoption by 
others. This thesis evaluates the quality of communication of patient innovators when sharing 
their solutions in designated online communities. Disparities in levels of communication 
among different innovation types were predicted and confirmed by our results.   
The applicability of user innovations in the health sector is one of great social interest and a 
topic we feel deserves more research focus. Given the potential of this particular type of 
innovators, it makes sense to have a platform designed to give them a voice and showcase 
their solutions. However, putting someone up on a stage is useless if they do not know how to 
express themselves, which is why we strongly believe the principles of effective 
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communication play a key role in the diffusion process of patient innovations shared in an 
online community.  
As seen in our Results section (pp. 27-28), patient developed solutions are not being 
effectively communicated. The biggest contributors to an average low communication index 
(M=4.92) are the items Relative Advantage and Trialability (table 20), as they are not being 
communicated at all in most cases. Both these attributes, Relative Advantage in particular, 
have been positively correlated with adoption (Tornatzky and Klein, 1982), meaning they are 
crucial in the decision to adopt, or not, an innovation. Consequently, if these characteristics 
are not even expressed in the description of a new solution, its potential of adoption 
automatically decreases. 
One major issue with the diffusion of user innovations is the lack of incentives to share 
(Kuusisto et al., 2013; von Hippel, 2005). Users develop with the purpose of self-benefit and 
rarely make the effort to share their solution with others. This behaviour happens not because 
user innovators are not willing to freely reveal their ideas, but instead because they are unable 
to see value in doing so. Research has shown how valuable to others, and to society as a 
whole, these consumer innovations can be, as the personal problems they solve might be 
similar to the ones faced by other consumers in the market. Henkel and von Hippel (2005) 
even classify the insufficient diffusion of user innovations as a welfare loss, because not 
disclosing these solutions is depriving, potentially, many others of benefiting from their use. 
Given the high degree of experience-based knowledge combined with more easily accessible 
technical knowledge, these new solutions are bound to be highly innovative. Our analysis 
shows that people who develop more radical innovations place more effort into 
communicating their solutions, so that these can be better understood by potential adopters. 
The same is true for solutions with higher degrees of complexity. Reasons behind this 
phenomenon might be related to the fact that innovators of simple solutions see them as 
obvious and unworthy of detailed explanation. 
With this work, we wish to inspire consumers to find solutions to their problems, when these 
are not available or in their reach. Teaching citizens the value of their personal experience and 
providing them with problem-solving tools to instigate their innovative and entrepreneurial 
side will most likely result in not only a more accomplished society, but also in economic 
gains. It is key to show innovators the importance of sharing their discoveries, which goes 




In practical terms, this study may help contribute to the increase in traction of the Patient 
Innovation website as well as the diffusion of the solutions in there shared. Currently, there is 
a lack of guidance regarding the sharing process; users are encouraged to do it, but a set of 
guidelines on how to do it successfully is not provided. Having effective communication 
theory in mind, we think this is one way of boosting diffusion, as more people will be able to 
successfully receive and understand the message being transmitted. Furthermore, users should 
be frequently reminded of the importance of their work and incentives should be established 
in order to feed their innovative conduct. 
5.1. Limitations 
The first limitation of this study is the sample, as the categorization process left us with 
different-sized groups. A broader sample would have granted results of higher statistical 
significance. Secondly, only three people were asked to rate the solutions, which in 
retrospective might not have been enough to eliminate bias. More raters would likely have 
yielded more reliable results. Finally, no data regarding adoption measures of the shared 
patient innovations was available to us, which would have helped to test our hypotheses and 
further support our conclusions. 
5.2. Future Research 
Studying adoption potential should be a predictive research, meaning forecasts should be 
made prior to implementation in order to avoid bias. Thus, a longitudinal study would be ideal 
to test the hypotheses and apply the model used in this thesis. Future research should be done 
to evaluate the conclusions of this study, by measuring the actual adoption rates of the 
innovations studied based on their levels of quality of communication. Furthermore, another 
study should be designed to explore why complexity impacts communication quality in a 
positive way. Moreover, it would be interesting to study the profiles of the innovators as an 
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